AL amyloidosis: untangling new therapies

Academic Article


  • Systemic light chain (AL) amyloidosis is a protein misfolding disorder characterized by the deposition of abnormal immunoglobulin light chains in fibrillary aggregates, resulting in end-organ damage. Several unique challenges face treating physicians, including delayed diagnosis, advanced vital organ involvement, and morbidity with treatment. Aggressive supportive care and risk-adapted application of plasma cell–directed therapies are the cornerstones of management. The therapeutic revolution in multiple myeloma will likely further expand the arsenal against plasma cells. Careful investigation of these agents will be critical to establish their role in this fragile population. The promise of fibril-directed therapies to restore organ function remains despite early disappointments. In this review, we discuss new therapies to tackle AL amyloidosis using a case-based approach.
  • Authors

    Published In

  • Hematology  Journal
  • Digital Object Identifier (doi)

    Author List

  • Bal S; Landau H
  • Start Page

  • 682
  • End Page

  • 688
  • Volume

  • 2021
  • Issue

  • 1